HT TBI
Alternative Names: HT-TBILatest Information Update: 16 Apr 2024
At a glance
- Originator Hoth Therapeutics
- Class Vascular disorder therapies
- Mechanism of Action Neurokinin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Stroke; Traumatic brain injuries